Xenetic Biosciences (XBIO)
(Delayed Data from NSDQ)
$3.97 USD
+0.22 (5.87%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.98 +0.01 (0.25%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.97 USD
+0.22 (5.87%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.98 +0.01 (0.25%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Zacks News
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 0% and 34.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 33.33% and 4.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ElectroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
electroCore (ECOR) delivered earnings and revenue surprises of 2.56% and 4.87%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 1.27% and 21.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 38.94% and 47.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 11.76% and 49.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Xenetic Biosciences (XBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -21.54% and 15.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Q1 Earnings Meet Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 0% and 4.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical Corporation (DERM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -67.65% and 11.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
VAXART, INC. (VXRT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 4.17% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cronos Group (CRON) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of -16.67% and 10.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 37.92% and 4.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Q2 Earnings Miss Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -90.08% and 0.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Xenetic Biosciences (XBIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Xenetic Biosciences (XBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.